International Eijkman Symposium on Tropi. Free delivery Arrives by Monday, Dec 2. Pickup not available. Add to List. Add to Registry. About This Item We aim to show you accurate product information. Manufacturers, suppliers and others provide what you see here, and we have not verified it. See our disclaimer.
Customer Reviews. Write a review. Ask a question. Pricing policy About our prices. We're committed to providing low prices every day, on everything. So if you find a current lower price from an online retailer on an identical, in-stock product, tell us and we'll match it. May be backordered or unavailable. We will update you with the status after you place your order.
A technique of targeting gene replacement in mouse embryonic stem cells has provided researchers with the ability to generate mutant mice defective in any specific gene. About the Author Sham im I. For about three decades he has been working in the field of DNA damage and repair particularly on Near UV photolysis of biological compounds, production of free radicals and their implications on human health including skin cancer and xeroderma pigmentosum.
The Frank lab continues to explore enzyme inhibitors, antibody reagents, and vaccines, which neutralize these damaging toxins.
Frank's work on the pathogenesis of F. October 26, - Fr iday. George Dimopoulos, Ph. Dimopoulos investigates vector control for malaria and dengue fever, examining the mechanisms through which the mosquito's immune system and its intestinal microflora block pathogens. The aim of the Dimopoulos group is to develop human pathogen resistant mosquitoes. The group has produced genetically modified "super-immune mosquitoes" that are resistant to malarial parasites.
Additionally, the group has identified intestinal bacteria in mosquitoes that block the malaria parasite and dengue virus. Dimopoulos completed his Ph. Seminar: Basic science and translational aspects of human pathogen elimination in mosquito vectors. November 2, - Friday. Jordan Hall - Reading Room. Timothy A.
Grese, Ph. In , Dr. His independent research contributions have focused on drug discovery in the areas of nuclear hormone receptors and therapeutics for osteoporosis and diabetes. Grese has been an innovator in the design and development of strategies and technologies advancing small molecule lead generation, including knowledge-based approaches to lead generation and structure-based design methodologies.
To date, Dr. Grese's oversight of Lilly's Open Innovation Drug Discovery program has resulted in the establishment of novel academic-industrial drug discovery partnerships with Notre Dame, UC-Irvine, the NIH and others and he is continuing to explore new public-private partnership in early-stage drug discovery. Grese holds a Ph.
November 16, - Friday.
Translational Medicine on Apple Podcasts
Ge ddes Hall RM B Vern B. Carruthers, Ph.
Carruthers studies the pathogenesis of toxoplasmosis, which is caused by the protozoan parasite Toxoplasma gondii. Carruther's team has identified parasite virulence factors that function in host cell invasion, immune evasion, nutrient acquisition and lytic egress from host cells causing tissue damage and inflammation. Additionally Carruther's team has demonstrated the efficacy of novel experimental compounds for treating the chronic phase of infection and identified a panel of biomarkers that reveal extensive neuroinflammation during chronic infection.
Carruthers completed his Ph. Seminar: Infection strategies of the highly successful neurotrophic parasite Toxoplasma gondii.
Padmini Salgame, Ph. Salgame investigates host immunity and pathogenic mechanisms in infectious diseases, particularly Th1 immunity in tuberculosis, interleukin, T cell polarization, and dendritic cells. Utilizing transgenic models, Dr. Salgame's lab is clarifying the mechanism underlying Th1 initiation in tuberculosis, identifying the relationships of dendritic cells, macrophages, and T cells. The aim of Dr. Salgame's research is to discover new modalities for vaccine development and therapeutics based on immune response.
Salgame completed her Ph. March 2, - RM Debartolo, pm. Marc C. Patterson, M. Patterson is board certified in psychiatry and neurology with special qualification in child neurology and in neurodevelopmentaql disabilities. Patterson investigates Niemann-Pick disease, type C NPC and other lysosomal diseases, and congenital disorders of glycosylation. Patterson's work explores the development of novel small molecule therapies for LSDs.
He was principal investigator of a prospective trial of miglustat in NPC and of a retrospective study of the use of miglustat in NPC in clinical practice. Currently, Dr. Patterson is participating in the development of therapeutic protocols for metachromatic dystrophy and globoid cell leukodystrophy. In addition to many other awards, Dr. Patterson graduated from the University of Queensland Australia medical school and his internship and earlier residency training Pediatrics, Internal Medicine, Neurology was at the Royal Brisbane and Royal Children's Hospitals in Queensland. Seminar: An introduction to neurometabolic disease.
March 9, - RM Debartolo, pm. Mary Dunkle. Dunkle has oversight for all of NORD's website, publications, educational activities, and research programs. She has more than 2 decades of experience in journalism and public relations in the arena of medical research and communications. Dunkle moved to her position at NORD over 12 years ago. NORD is a national nonprofit organization comprising a federation of voluntary health organizations which serve the rare disease communities. NORD's mission is aimed at the identification, treatment, and cure of rare diseases through education, advocacy, research, and service.
Dunkle describes the NORD website as "the central communications hub for patients, support organizations, medical professionals, policymakers and industry on topics related to rare diseases and orphan products. April 13, - RM Debartolo, pm. Heiko Runz, M. Runz is a principal investigator and medical geneticist. Runz special interests include: cell biology of cholesterol metabolism and associated diseases; functional analysis of lysosomal storage disorders by advanced light-microscopy technology; identification of modifier genes for monogenetic lipid metabolic disorders. Runz currently co-leads the fifth of MMPU's 5 international teams, which is aimed at researching cell biology and disorders of cholesterol homeostasis.
Seminar: Niemann-Pick type C disease - from bedside to bench and back. April 20, - RM Debartolo, pm. Jacqueline Imrie, MSc. Clinical Nurse Specialist Paediatrics.
Related Tropical Diseases: From Molecule to Bedside (Advances in Experimental Medicine and Biology)
Copyright 2019 - All Right Reserved